Thursday, 27 January 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (10)

Sales & Customer Relations (29)

Access & Reimbursement (1)

Clinical & Medical, R&D (16)

Regulatory, Pharmacovigilance & QA (6)

Other (17)

News

Sell-off rumours circle AZ

 Posted December 7, 2021 PM

AstraZeneca is the latest big pharma said to be considering carving off part of its business into a separate entity, with the company's newly formed COVID-19 vaccine and antibody treatment unit tipped as ripe to spin out on its own.

Just last month the company set up the new division which would take control of the company's vaccine Vaxzevrvia and its long acting antibody Evusheld as well as several other respiratory infection treatments.

To see the whole article, please login

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.